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ABSTRACT
Vascular endothelial growth factor (VEGF) expression is associated with 
malignancy progression, metastasis, and poor prognosis in many malignancies, 
including osteosarcoma. However, studies concerning correlations between 
VEGF expression and histopathological prognostic factors of osteosarcoma 
are limited. This study aimed to evaluate the correlations between VEGF 
expression and histopathological findings in osteosarcoma’s patients. This was 
a cross-sectional study using formalin-fixed paraffin embedded (FFPE) samples 
of 32 osteosarcoma’s patients from Dr. Sardjito General Hospital, Yogyakarta. 
Histopathological findings of specimens were re-evaluated by two independent 
observers, recorded for the subtypes, invasiveness, grading, mitotic counts, 
and tumor infiltrating lymphocytes (TIL). Expression of VEGF was determined 
based on immunostaining and evaluated using immunoreactivity score (IRS).
Chi-square and Spearman correlation test were used to analyze the association 
between variables. Range of VEGF expression score was 0 to 11, with mean 
5.09. Significant negative correlation between the VEGF expression and TIL was 
observed (p=0.046). However, there was no significant correlations between 
the VEGF expression and osteosarcomas subtypes, invasion, grading or mitotic 
counts (p> 0.05). In conclusion, the VEGF expression is associated with TIL. 
Further study is needed to evaluate the roles of VEGF and lymphocytes in 
osteosarcoma development dan progression in order to better understand of 
the role of VEGF in immunotherapy of osteosarcoma. 
ABSTRAK
Ekspresi vascular endothelial growth factor (VEGF) dikaitkan dengan 
progresivitas, metastasis, dan prognosis yang buruk pada keganasan, termasuk 
osteosarkoma. Namun demikian, penelitian tentang hubungan antara 
ekspresi VEGF dengan faktor prognosis histopatologi pada osteosarkoma 
belum banyak dilakukan. Penelitian ini bertujuan mengkaji hubungan 
antara ekspresi VEGF dengan gambaran histopatologi pada osteosarkoma. 
Penelitian ini merupakan penelitian potong lintang menggunakan sampel 
formalin-fixed parafin embedded (FFPE) dari 32 kasus osteosarkoma di Rumah 
Sakit Umum Pusat Dr. Sardjito, Yogyakarta. Gambaran histopatologi berupa 
sub tipe, invasi limfovaskular, grading, jumlah mitosis, dan tumor infiltrating 
lymphocytes (TIL) dievaluasi oleh dua penilai independen. Ekspresi protein 
VEGF ditentukan berdasarkan pengecatan imunohistokimia dan dievaluasi 
dengan immunoreactive score (IRS). Uji korelasi Spearman dan uji Chi-square 
digunakan untuk menganalisa hubungan antar variabel. Skor ekspresi VEGF 
bervariasi dari 0-11, dengan skor rata-rata 5,09. Terdapat hubungan signifikan 
secara negative antara ekspresi VEGF terhadap TIL (p=0,046; r: -0,355). Namun 
demikian, tidak ada hubungan signifikan antara ekspresi VEGF terhadap 
sub tipe, invasi limfovaskular, grading atau jumlah mitosis (p>0,05). Dapat 
disimpulkan, ekspresi VEGF berhubungan dengan TIL. Penelitian lebih lanjut 
diperlukan untuk mengkaji peran VEGF dan limfosit dalam progresivitas dan 
perkembangan osteosarkoma untuk lebih memahami peran VEGF dalam 
imunoterapi osteosarkoma. 
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INTRODUCTION
Osteosarcoma is the most frequent 
primary bone malignancy in adolescents 
and young adults, and is derived from 
bone-forming mesenchymal cells. 
Although it is not a frequent type of 
tumor, it has a devastating effect on 
patients. Survival has not improved 
significantly over the past three decades, 
and osteosarcoma with metastasis 
is usually incurable and requires 
palliation.1 Surgery and chemotherapy 
are the current standard treatments 
for osteosarcoma. Despite multimodal 
therapies, over 40% of patients fail to 
be treated within 5 years of diagnosis, 
generally due to distant spread of tumor.2
New vascular formation is 
essential in the growth and spreading of 
the tumor. The most important protein 
involved in tumor angiogenesis is 
vascular endothelial growth factor (VEGF) 
because it acts by increasing all steps 
in angiogenesis.3 The VEGF expression 
is associated with cancer progression, 
metastasis, and worse prognosis in 
many tumors. Overexpression of 
the VEGF is significantly correlated 
with tumor growth and prognosis of 
cancer patients.3 Enzymes of VEGF 
stimulate tumor growth and metastatic 
processes by its interactions with 
metalloproteinase.4 In contrast, VEGF 
inhibition leads to suppression of cancer 
proliferation, stimulating apoptosis, 
reducing angiogenesis5 and decreasing 
vascular density in malignant tumors 
while increasing the efficacy of adoptive 
T-cell therapy in certain cancers.6
Some histopathologic features of 
osteosarcoma have served as prognostic 
factors, including tumor subtype, 
nuclear pleomorphism, mitotic rate, 
lymph-vascular invasion, tumor fibrosis, 
and tumor viability after chemotherapy.7 
Tumor infiltrating lymphocytes (TIL) are 
also an important prognostic factor in 
many tumors and the presence of TIL in 
sarcoma positively correlates with a good 
prognosis.8 Several studies regarding 
VEGF expression and the prognosis 
of osteosarcoma patients have been 
performed previously, however, there 
are contradictive results among studies.9 
Thus, there were various results among 
studies investigating association of VEGF 
expression with survival and other 
prognostic factors in osteosarcoma. 
This study analyzed the 
correlation of VEGF expression 
with histopathological findings in 
osteosarcoma patients, including 
histopathologic subtype, grading, lymph 
vascular invasion, mitotic count, and TIL. 
To the best of our knowledge, this study 
is the first to correlate VEGF expression 
with TIL, mitotic count, and lymph 
vascular invasion in osteosarcoma 
obtained from human tissue. This study 
aimed to evaluate correlations between 
VEGF expression and histopathological 
findings in osteosarcoma to achieve 
better understanding of its pathogenesis 




This cross sectional study was 
conducted at Dr. Sardjito General 
Hospital, Yogyakarta. This study has been 
approved by the Medical and Health 
Research Ethics Committee at the Faculty 
of Medicine, Public Health and Nursing, 
Universitas Gadjah Mada, Yogyakarta 
(Ref: KE/FK/1107/EC/2018). The subjects 
of this study were 32 patients who were 
diagnosed with osteosarcoma based on 
clinical, radiological, histopathological 
examinations and confirmed by 
osteocalcin immunostaining. Samples 
were recruited by total sampling 
technique, using formalin-fixed paraffin 
embedded (FFPE) tissue blocks archived 
from between 2012 to 2018. Data were 
analyzed based on the histopathological 
and immunohistochemistry (IHC) 
examinations performed at the 
Laboratory of Anatomic Pathology, Dr. 
Sardjito General Hospital, Yogyakarta.
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Histopathological finding assessment 
The slides were reviewed by two 
independent observers with standard 
hematoxylin-eosin (HE) staining to 
identify histopathologic subtypes, 
grading, mitotic count, lymph vascular 
invasion, and TIL. Kappa value 
of inter-observer agreement was 
measured. Discordancy, if any, were 
reconciled through group discussion. 
Histopathological subtypes and grade 
were divided based on the World Health 
Organization (WHO) Classification of 
Tumors of Soft Tissue and Bone 2013.10 
Mitotic count and lymph vascular 
invasion were analyzed as dichotomous 
variables. Mitotic count was divided into 
low mitotic count (<20/10 high power field 
(HPF)) and high mitotic count (>20/10 
HPF).6 Tumor infiltrating lymphocytes 
in this study was defined as the 
percentage of peritumoral stromal area 
occupied by mononuclear cells including 
lymphocytes and plasma cells (areas of 
necrosis and fibrosis were not included; 
granulocytes and polymorphonuclear 
leukocytes were excluded), and divided 
into minimal (0-10%), intermediate (10-
40%), and high (more than 40%).11 The 
categoric scale of the data was used in 
the statistical analysis.
IHC staining assessment
The VEGF expression was evaluated 
based on immunostaining technique. 
FFPE samples were sliced 3um, and then 
incubated with primary antibody against 
VEGF (1:100 dilution; Finetest, Fine 
Biotech). Subsequently, the sections were 
incubated with Ultra Tek Anti-Polyvalent, 
followed by Ultra Tek HRP, which formed 
a complex. Diaminobenzidine was used 
as the final chromogen, and hematoxylin 
was used as the nuclear counterstain. 
The VEGF expressions were evaluated 
based on staining intensity and 
percentage of positive cells using the 
immuno reactivity score (IRS) scoring as 
described by Fedchenko study.12 Positive 
staining was shown in cell membranes 
and cytoplasm. Score of positive cells 
percentage was multiplied by score 
of staining intensity, then divided in 
categoric scale into: negative, mild 
positive, moderately positive, or strongly 
positive (TABLE 1).






of A and B)
0 = no positive cells 0 = no color reaction 0-1= negative
1= <10% positive cells 1 = mild reaction 2-3 = mild positive
2 = 10-50% positive cells 2 = moderate reaction 4-8 = moderately positive
3 = 51-80% positive cells 3 = intense reaction 9-12 = strongly positive
Statistical analysis
Statistical analysis was performed 
using SPSS Statistics version 25 
(IBM Corp., Chicago). Kappa value 
was used to measure agreement 
between two independent observers 
of histopathological findings in 
osteosarcoma. Correlation between 
VEGF expression and histopathological 
findings were analyzed statistically 
using Spearman correlation test if 
both variables were ordinal, otherwise 
Chi-square test was used to analyze 
association between nominal and ordinal 
variables. A p-value of 0.05 or less was 
considered as statistically significant.
RESULTS
Tumor subtype
Among 32 FFPE samples evaluated, 
25 samples (78%) were conventional 
osteosarcoma, including 10 samples 
(31.3%) of chondroblastic variant, 7 
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samples (21.9%) of osteoblastic variant, 
while 7 samples (21.9%) were fibroblastic 
variant, 4 samples (12.5%) were giant cell 
rich variant, and 1 sample (3.1%) was 
epithelioid variant. Other subtypes were 
observed including parosteal, periosteal, 
and telangiectatic variant, with 1 sample 
each (FIGURE 1).
FIGURE 1. Osteosarcoma variant found in this study: (A). Osteoblastic, with 
dominance of  osteoid matrix. (B). Chondroblastic, with a lot of chondroid 
matrix. (C). Fibroblastic, consist of spindle cell tumor. (D). Giant cell 
rich, with a lot of osteoclastic type giant cells. (E). Telangiectatic type, 
with dilated vascular space. (F). Parosteal, low grade osteosarcoma 
with mild polymorphism of tumor cells. (G). Periosteal, intermediate 
grade osteosarcoma with moderate polymorphism of tumor cells.  (H). 
Epithelioid, high grade osteosarcoma with epithelioid morphology, in 
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Histopathological finding and VEGF 
expression 
Kappa value measurement 
between two independent observers 
of histopathological findings in 
osteosarcoma yielded the following 
results: subtype (0.843), grade (1.000), 
invasion (0.776), mitotic count (0.834), 
and TIL (0.824). Invasion to blood or 
lymph vessels was found in 23 samples 
(71.9%). Nine samples were without 
blood or lymph vessels invasion. High 
grade tumors were found in 26 (81.3%) 
samples, moderate grade in 4 (12.5%) 
samples, and low grade in 2 (6.3%) 
samples. Among all samples, mitotic 
count was analyzed and ranged from 
1/10 high power field (HPF) to 40/10 HPF. 
There were 25 samples (78.1%) with low 
mitotic counts (<20/10HPF) and 7 samples 
(21.9%) with high mitotic counts. As for 
TIL, 26 samples (81.3%) showed minimal 
TIL, 5 samples (15.6%) were with 
intermediate TIL, and 1 sample (3.1%) 
had high TIL (TABLE 2, FIGURE 2). 
TABLE 2. Histopathological findings in osteosarcoma






















FIGURE 2. Tumor Infiltrating Lymphocytes (TIL) in osteosarcoma (A). Mild TIL with 
lymphocyte infiltration 0-10%, (B). Intermediate TIL with lymphocyte 
infiltration 10-40%, (C). High TIL with lymphocyte infiltration more than 40%
A B C
Vascular endothelial growth factor 
expressions were assessed using IRS 
score. The VEGF expression in 32 samples 
showed IRS from 0 to 11 (maximum IRS 
score: 12), with mean 5.09. Four samples 
(12.5%) were negatively stained with 
anti-VEGF antibody, 10 samples (31.3%) 
were mildly positive, 13 samples (40.6%) 
were moderately positive, and 5 samples 
(15.6%) were strongly positive (FIGURE 
3).
115
J Med Sci, Volume 53, Number 2, 2021 April: 110-120
FIGURE 3. Representative images of immunohistochemistry staining in different 
level of VEGF expression. The degree of expression was determined by 
intensity of staining and percentage of positively stained cells (IRS score, 
as described in TABLE 1); (A) Strongly positive, (B) Moderately positive, (C) 
Mildly positive, (D) Negative. White bar: 200 µm.
A B
C D
Vascular endothelial growth factor 
expression and TIL showed statistically 
significant correlation (p=0.046), with 
correlation coefficient: -0.355, indicating 
negative correlation between VEGF and 
TIL. Thus, tumors with high expression of 
VEGF tended to have lower TIL. Analysis 
on histopathologic subtype, invasion, 
grading, and mitotic count showed no 
significant correlation with the VEGF 
expression (TABLE 3 and 4).
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TABLE 3. Correlation between VEGF expression and histopathological 




r pNegative Mild Moderate Strong
Grade
•	Low 1 1 0 0
0.042 0.819•	Moderate 0 0 1 0
•	High 4 9 12 5
Mitotic count
•	<20/10HPF 3 6 13 3
-0.085 0.480
•	>20/10HPF 1 4 0 2
TIL
•	Minimal 3 6 12 5
-0.355 0.046•	 Intermediate 0 4 1 0
•	High 1 0 0 0





Negative Mild Moderate Strong
Subtypes
•	 Osteoblastic 0 3 3 1
0.808
•	 Chondroblastic 1 4 3 2
•	 Fibroblastic 2 1 3 1
•	 Parosteal 0 1 0 0
•	 Periosteal 0 0 1 0
•	 Teleangiectatic 0 0 0 1
•	 Giant cell rich 0 1 3 0
Lymph vascular invasion
•	 Epithelioid 1 0 0 0
0.812•	 Negative (-) 1 3 3 2
•	 Positive (+) 3 7 10 3
DISCUSSION
Based on histopathological type, 
conventional osteosarcoma comprised 
78% of the tumors in this study. Based 
on further morphological observation 
on subtypes, the most common type 
of the conventional osteosarcoma was 
chondroblastic variant (31.3%), followed 
by osteoblastic and fibroblastic variants 
(each 21.9%), giant cell rich variant 
(12.5%) and epithelioid variant (3.1%). 
However, these findings are remarkably 
different with the report in the WHO 
Classification of Bone and Soft Tissue 
Tumorbook as it stated that osteoblastic 
variant is the most common subtype, 
followed by chondroblastic, fibroblastic, 
and other subtypes.13 This difference can 
be attributed to different geographical 
location, race, and sample size.
Most of the osteosarcoma in our 
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study were comprised of highgrade 
tumors (93.8%), followed by moderate 
grade tumors and low grade tumors (each 
3.1%). This finding was concordant with 
the previous reportthat showed high 
grade osteosarcoma asthe majority cases 
(92-93%), where as low and intermediate 
grade were only 7-8%.10
More advanced disease is 
represented by positive lymph vascular 
invasion (LVI) and our study found that 
majority of cases (71.9%) were with 
positive LVI. In developed countries, 
such as Canada8 lymph vascular invasion 
was observed in only 27% of the cases. 
Different onsets at diagnosis period and 
patient behavior in seeking medical 
professional help may contribute to the 
various findings among those studies. 
In developing countries where there 
are more barriers for accessing health 
care, advanced stage is found more often 
compared to developed countries.14
Osteosarcomas with low mitotic 
rate (<20/10HPF) are the majority type 
in our study (78.1%). A study in Canada 
showed a similar resultas 86% of the 
osteosarcoma showing low mitotic rate.5 
Osteosarcoma with higher mitotic rate 
significantly has worse prognosis.6 The 
majority of osteosarcoma cases in our 
study show minimal or intermediate TIL 
(81.3% and 15.6, respectively). Previous 
study also reported that the majority of 
osteosarcoma had low or no TIL.17 Some 
neoplasms have a mechanism to promote 
tumor growth through cell contact or 
paracrine secretion of cytokines, growth 
factors, and nutrients. Some secreted 
cytokines may influence tumor-induced 
immunosuppression. During the tumor 
development, an inhibitory program 
for T-cell activation has been activated. 
Immunosuppressive mechanisms in the 
tumor microenvironment involve the 
suppressive action of regulatory T-cells 
(Tregs), myeloid-derived suppressor 
cells (MDSCs), tumor-associated 
macrophages (TAMs), and stromal 
fibroblasts. These cells suppress T-cell 
function by increasing expression of 
surface molecules that bind to the 
inhibitory receptors, such as cytotoxic 
T lymphocyte-associated protein 4 
(CTLA-4), programmed cell death 
protein 1 (PD-1), T cell transmembrane, 
immunoglobulin, mucin (TIM-3), 
lymphocyte-activation gene 3 (LAG-3), 
B and T lymphocyte associated (BTLA) 
protein,7 resulting in low number of 
TIL in osteosarcoma, quantitatively and 
qualitatively.
Positive VEGF expressions were 
found in 87.5% of the samples. Most 
of them were moderately positive 
by the IRS scoring system. Many 
studies assessing VEGF expression 
in osteosarcomas revealed different 
results ranging from 20% to 93%. The 
thresholds of VEGF positivity were also 
different across many studies, ranging 
from 10% to 50% of tumor cells. The 
scoring systems used were also different. 
Some used only percentage of positive 
cells, while others used complex scoring 
combining intensity and percentage.15 
Until recently, there is no single widely 
accepted scoring system to assess VEGF 
expression in osteosarcomas. Vascular 
endothelial growth factor expression 
is shown to have significant negative 
correlation with TIL. Our finding shows 
that tumors with low TIL tend to have 
higher VEGF expression. Theoretically, 
high level of VEGF expression initiates 
endothelial cell proliferation, which 
leads to higher density but structurally 
and functionally abnormal vessels. 
These vessels have irregular, twisted 
shape, and are leaky. Although acute 
VEGF stimulation acts as up-regulator for 
adhesion molecules and thereby causing 
leukocyte infiltration, where as chronic 
VEGF exposure may inhibit interaction of 
endothelial and leukocytes by lowering 
expression of adhesion molecules, such 
as vascular cell adhesion molecule-1 
(VCAM-1), intercellular adhesion 
molecule-1 (ICAM-1), and E-selectin. 
VEGF suppress lymphocyte infiltration 
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through inhibition of C-X-C motif ligand 
10 (CXCL10) and C-X-C motif ligand 11 
(CXCL11), which are both chemokines 
involved in T-cell recruitment.16 VEGF 
also decreases proinflammatory 
cytokines’ responsiveness surrounding 
endothelial cells by  repressing nuclear 
factor (NF)-κB pathways. Inhibition of 
VEGF, in contrast, as shown in many 
studies, stimulates the interaction 
of leukocytes and endothelial cells 
by increasing adhesion molecules 
expression. Sunitinib, a VEGF inhibitor, 
acts as an up-regulator for inflammatory 
genes CXCL10 and CXCL11 that leads 
to increased T-cell infiltration. Thus, 
VEGF acts as a barrier for leukocyte 
infiltration.16
The presence of high numbers of 
cytotoxic T lymphocytes in the tumors 
correlates with better outcomes. There 
is also positive correlation of TIL and 
programmed cell death ligand-1 (PDL-
1) gene expression in osteosarcoma.17 
The ability of T-cells to recognize, 
localize, and kill tumor cells is very 
promising in cancer immunotherapy 
research. Vascular endothelial growth 
factor inhibits maturation and reduces 
number of dendritic cells. It also 
inhibits differentiation of progenitor 
cells into CD4/CD8+ve T cells, suppress 
proliferation and cytotoxic functions, and 
upregulates programmed cell death-1 
(PD-1), CTLA-4, TIM3 and LAG3. Anti-
VEGF, such as bevacizumab or sorafenib, 
may block immunosuppressive effects of 
angiogenic protein and enhance immune 
cell therapeutic effect on neoplasms. 
Its combination with immunotherapy 
drugs, such as nivolumab, 
pembrolizumab, atezolizumab, and 
avelumab, shows synergic effects in 
enhancing the activity of cytotoxic T-cells 
on tumor cells.18 The finding regarding 
significant correlation between VEGF 
expression and TIL provides a valuable 
opportunity to explore the role of VEGF 
and lymphocytes in osteosarcoma 
development and progression which can 
lead to better understanding of VEGF 
role in osteosarcoma immunotherapy.
This study showed no significant 
association between VEGF expression 
with tumor subtypes, grade, lymph 
vascular invasion, and mitoticcounts. 
Similar previous study revealed that 
there was no association between 
VEGF expression and tumor grade in 
osteosarcoma.19 However, other study 
showed significant associations between 
VEGF-C expression with histopathological 
subtypes and grading in osteosarcoma.20 
Previous in-vitro study in osteosarcoma 
cell lines showed that VEGF correlates 
with tumor growth as VEGFR inhibition 
resulted in the decreases of osteosarcoma 
proliferation and invasion.21 Different 
result in some studies can be attributed 
to different microenvironments between 
in-vitro cell lines and human tissue. 
Various quantification techniques of 
VEGF expression may also contribute to 
different results among studies. 
CONCLUSION
This study shows significant 
correlation between VEGF expression 
and TIL, however, its correlation 
with tumor subtypes, grading, and 
mitoticcountin osteosarcoma patientsis 
not observed. Correlation between 
TIL and VEGF expression infers that 
VEGF has immunosuppressive effect in 
the osteosarcoma microenvironment 
through inhibition of lymphocyte 
infiltration in the peritumoral area. 
Further study is needed to investigate 
the effect of anti-VEGF on alteration of 
T-cells cytotoxic activity in osteosarcoma 
cells. 
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